Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Abstract

The administration of drotrecogin alfa (activated) to patients with severe sepsis was associated with a significant survival benefit that tended to increase with higher baseline likelihood of death. Current data suggest that the increased risk of bleeding does not vary according to likelihood of death.